Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal ...
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal ...
1. Ponsegromab significantly increased body weight in patients with cancer cachexia and elevated GDF-15 levels compared to placebo at 12 ...
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
NPI Lookup · Free
Search by name or NPI number, live from the CMS NPI Registry.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free
Then $49.90/year.
Already a member? Sign in